Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
about
Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
P2860
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@en
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@nl
type
label
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@en
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@nl
prefLabel
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@en
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@nl
P2093
P2860
P1476
Cost-effectiveness of adding c ...... myeloma from a US perspective.
@en
P2093
Andromachi Giannopoulou
Andrzej J Jakubowiak
Beth L Barber
Eszter Tichy
Ivan Houisse
Marco Campioni
Sanjay K Aggarwal
Sumeet Panjabi
Ágnes Benedict
P2860
P304
P356
10.1080/13696998.2016.1194278
P407
P577
2016-05-25T00:00:00Z